Strong growth forecast for RSV prophylactic market

The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM; USA, France, Germany, Italy. Spain, the UK and Australia) is forecast to grow at a compound annual growth rate (CAGR) of 26.7% from $582 million in 2020 to $6.2 billion in 2030, with the pediatric and adult segments accounting for $2.2 billion and $4.0 billion, respectively, according to pharma analytics company GlobalData.

GlobalData’s latest report, “Respiratory Syncytial Virus Prophylaxis: Eight-Market Drug Forecast and Market Analysis – Update,” reveals that market growth will primarily be driven by the uptake of new monoclonal antibodies (MAbs), as well as maternal, adult, and pediatric RSV vaccines.

In 2020 the only product marketed for RSV prophylaxis was AstraZeneca (LSE: AZN) and AbbVie's (NYSE: ABBV) Synagis (palivizumab), a MAb only used in high-risk infants. However, the prophylactic landscape will see heavy diversification over the forecast period, with the launch of multiple novel products.